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OBJECTIVES: According to the recent international data, the incidence of blood-
stream catheter—associated infections is 3–8% in the structure of hospital- acquired 
infections in the intensive care units (ICU) and the leading cause of them are Gram 
positive bacteria. In this study we conducted comparative analysis of clinico—eco-
nomic effectiveness of daptomycin (dapto) vs. vancomycin (vanco) usage in treatment 
of patients with MRSA catheter—associated infection in the ICU. METHODS: “Deci-
sion Tree” pharmacoeconomic model was built based on results of international clini-
cal studies and data of routine practice treatment of bloodstream infections in Moscow 
clinics. Two variants of antibacterial treatment of patients with catheter-associated 
infections differing on starting products (dapto or vanco) were assessed. If the ﬁ rst 
line of therapy was ineffective, patients switched over to the second line therapy cover-
ing resistant strains—meropenem and ﬂ uconazole. Direct and indirect medical costs 
were assessed: cost of antibiotics and additional medical treatment, antibacterial 
diagnostic, laboratory and cost of bed-days in ICU and therapeutic department. Costs 
were based on ofﬁ cial data on hospital medical service in municipal Moscow clinics 
and purchasing price on medical products from price list of the biggest Russian phar-
maceutical distributors. Clinical recovery was considered as efﬁ cacy with the goal to 
evaluate cost-effectiveness ratio (CER) of two groups (CERdapto and CERvan accord-
ingly). RESULTS: Better clinical efﬁ cacy in daptomycin group resulted in lower—
needs to change antibiotic in catheter—associated infection treatment in the ICU in 
comparison to vancomycin group. In spite of the higher price of drug, average cost 
of successfully treated patient by daptomycin (CERdapto) was 227,887 RUR/pt in 
compare with CERvan 235,032 RUR/pt. Exchange rate is 1USD = 30 RUR. CON-
CLUSIONS: Good cost-effectiveness ratio in comparison to vancomycin supports use 
of daptomycin as the ﬁ rst line antibacterial therapy in bloodstream catheter—associ-
ated infections.
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OBJECTIVES: The objective of the study was to evaluate the cost-effectiveness of 1 
year peginterferon alfa-2a compared to 4 years entecavir for the treatment of HBeAg-
positive chronic hepatitis B in China. METHODS: A Markov health-state model was 
designed to evaluate the direct medical costs and outcomes (life-years and QALYs 
gained) of treating HBeAg-positive chronic hepatitis B in China. The model included 
10 health states—Chronic hepatitis B (CHB), HBeAg seroconversion, HBsAg loss, 
CHB with resistance, Compensated cirrhosis, Decompensated cirrhosis, Hepatocel-
lular carcinoma, Liver transplant, Post-liver transplant and death. The model incor-
porates a maximum analysis time horizon of 80 years with yearly cycles. The clinical 
and quality of life data were obtained from published literature and re-conﬁ rmed 
based on a questionnaire survey from a clinical expert panel of 20 hepatitis B special-
ists. From the perspective of China’s health insurance system, cost data was calculated 
based on the published literature about economic burden of chronic hepatitis B. a 
discounting rate at 3% was used to discount utilities and medical costs happened at 
different years. a univariate sensitivity analysis was performed to understand the key 
drivers and general sensitivity of the model. RESULTS: The model results showed that 
the utilization of 1 year peginterferon alfa-2a treatment for HBeAg-positive CHB can 
prolong 0.32 QALYs, compared to the 4 years entecavir treatment (16,394 QALYs 
vs. 16,074 QALYs). The total cost per patient treated with peginterferon alfa-2a was 
US$22,221, and US$19,989 for patient treated with entecavir. The discounted incre-
mental cost per QALY gained for pegainterferon alfa-2a was US$6965. CONCLU-
SIONS: The results of the model suggest that 1 year pegainterferon alfa-2a improves 
health outcomes in a cost-effective manner compared with 4 years entecavir in the 
treatment of HBeAg-positive chronic hepatitis B in China.
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OBJECTIVES: To estimate long-term cost-effectiveness of treatment of chronic hepa-
titis C (CHC) patients with peginterferon alfa-2a (180 mcg/week) versus peginterferon 
alfa-2b (1.5 mcg/kg/week) both in combination with ribavirin (800–1400 mg/day) 
from the Spanish National Healthcare System perspective. METHODS: A meta-
analysis of head-to-head randomized trials of peginterferon alfa-2a and peginterferon 
alfa-2b both plus ribavirin, evaluating sustained virological response (SVR) has been 
recently published. It showed RR = 1.11 (95%CI 1.04–1.19) for all genotypes, RR = 
1.21 (95%CI 1.03–1.42) for G-1/4, and RR = 1.11 (95%CI 1.02–1.22) for G-2/3. a 
Markov model with 7 health states was developed to simulate the disease progression 
of adult patients with CHC for a lifetime horizon. Efﬁ cacy, in terms of SVR, was 
calculated from the meta-analysis, showing a better SVR rate for peginterferon alfa-2a 
than for peginterferon alfa-2b: the absolute differences were of 6.0%; 7.6%; and 8.7% 
for all genotypes, G-1/4 and G-2/3 respectively. Transition probabilities and health 
states utilities were obtained from published literature. Health direct costs of pegin-
terferon + ribavirin (48 weeks for G-1/4 and 24 weeks for G-2/3) and of disease 
complications were collected from Spanish databases and studies ([c] 2010). The 
annual discount rate was 3.5% for costs and outcomes. RESULTS: Each patient 
gained 0.469, 0.600 and 0.685 life-years (LY) and 0.155, 0.198 and 0.227 quality-
adjusted life-years (QALY) with peginterferon alfa-2a in comparison with peginter-
feron alfa-2b, for all genotypes, G-1/4 and G-2/3 respectively. The savings per patient 
treated with peginterferon alfa-2a were c705, c672 and c1900, for all genotypes, 
G-1/4 and G-2/3, respectively. Peginterferon alfa-2a was the dominant treatment 
strategy (lower costs and higher efﬁ cacy than peginterferon alfa-2b treatment). 
CONCLUSIONS: Treatment of patients with chronic hepatitis C with peginterferon 
alfa-2a + ribavirin is a cost-effective strategy in comparison with peginterferon alfa-2b 
+ ribavirin for all genotypes, G-1/4 and G-2/3.
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OBJECTIVES: Kiovig is a new, ready-to-use 10% liquid immunoglobulin preparation 
that is medically indicated for the treatment of primary immunodeﬁ ciency. This study 
aims to conduct an economic evaluation which compares the intravenous immuno-
globulin (IVIg) preparations Kiovig, Multigam, and Sandoglobulin from the Belgian 
societal perspective. METHODS: Given that three prospective studies have observed 
no difference in outcomes, a cost-minimization analysis considered the differences in 
costs that can arise from these immunoglobulin products. a decision-analytic model 
simulated immunoglobulin treatment over a one-year time horizon. Cost items 
included immunoglobulin costs, pharmacy administration and nursing costs, mini-
forfait paid for hospital infusion, costs of adverse events, and lost productivity. Cost 
data were identiﬁ ed from published sources and Belgian hospital administrators. a 
probabilistic sensitivity analysis explored the impact of parameter uncertainty. The 
price year was 2009. RESULTS: Costs per infusion cycle in adult primary immuno-
deﬁ ciency patients were c1.046 (95% conﬁ dence interval: c1.006–1.093) with Kiovig; 
c1.102 (c1.064–1.147) with Multigam; and c1.147 (c1.108–1.193) with Sandoglobu-
lin. The average cost savings per infusion with Kiovig as compared to Multigam and 
Sandoglobulin amounted to c56 and c101 per infusion. CONCLUSIONS: Treatment 
costs with Kiovig were shown to be lower as compared to other IVIgs in Belgium. 
Reduced costs per infusion were attributed to lower costs associated with treating 
adverse events and the opportunity cost of nursing time and time off work for working 
adults.
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OBJECTIVES: To evaluate cost-effectiveness of pneumococcal non-typeable Hae-
mophilus Inﬂ uenza protein D conjugate vaccine(PHiD-CV), 7-valent pneumococcal 
conjugate vaccine(PCV7), and PCV13 in Taiwan. METHODS: An age-compartmen-
tal, deterministic, static cohort model simulated in a 198,733 birth cohort the disease 
process of invasive disease(ID, meningitis and bacteremia), community acquired 
pneumonia(CAP), and acute otitis media(AOM) over life-time. The model was devel-
oped by GlaxoSmithKline and adapted with local data. For base-case analysis for all 
vaccines, a 4-dose(3 + 1) schedule was assumed with 95% vaccine coverage. Cost and 
outcomes were analyzed from health care payer perspective with 3% discount rate. 
Herd protection on ID, limited cross protection against 6A and 19A, minimal estima-
tion of NTHi(non-typeable Haemophilis Inﬂ uenzae) infection rates in ID and CAP 
were assumed for base case. Costs for PHiD-CV, PCV7 and PCV13 were assumed 
parity at 3200 New Taiwan Dollar(NTD). Epidemiological and cost data were 
obtained from local disease burden study. Vaccine efﬁ cacy data were obtained from 
published sources. One way and probabilistic sensitivity analyses were conducted. 
RESULTS: Compared with PCV7, PHiD-CV is expected to prevent additional cases 
of 1 ID, 2,291 CAP and 63,597 AOM, with 548 additional quality-adjusted life-
years(QALY) gained with total saving of NTD 69,347,211. Compared with PCV13, 
PHiD-CV is expected to prevent less cases of 4 ID and 264 CAP, but expected to 
prevent additional 45,111 AOM cases. PHiD-CV is expected to provide additional 
181 QALY gained with total saving of NTD 14,532,124 compared to PCV13. Sensi-
tivity analyses show the results are most sensitive to the changes of AOM related 
parameters, but when the AOM related parameters were changed up to +/− 20%, 
PHiD-CV is still cost-saving to PCV7 and PCV 13. CONCLUSIONS: PHiD-CV is 
expected to provide more QALYs with potential saving of total health care cost 
